Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitsuo Sato

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Molecular Cancer Therapeutics|February 11, 2011
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapyNoriaki Sunaga, David S Shames, Luc Girard, et al.
Experimental Cell Research|February 12, 2022
Resistance to mutant KRAS<sup>V12</sup>-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell lineNao Muraki, Mizuki Yamada, Hinako Doki, et al.
Annals of Surgical Oncology|November 17, 2011
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cellsMihoko Horio, Mitsuo Sato, Yoshihiro Takeyama, et al.
Oncology Letters|August 21, 2023
Silencing of <i>GRHL2</i> induces epithelial‑to‑mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growthNozomi Kawabe, Kohei Matsuoka, Kazuki Komeda, et al.
Plos One|November 16, 2020
Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patientsNaoyuki Yogo, Tetsunari Hase, Toshihiro Kasama, et al.
Respiratory Investigation|February 11, 2026
Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitorsTatsuya Hirano, Ichidai Tanaka, Masahiro Morise, et al.
IEEE Transactions on Biomedical Circuits and Systems|November 27, 2018
A 65-nm CMOS Fully Integrated Analysis Platform Using an On-Chip Vector Network Analyzer and a Transmission-Line-Based Detection Window for Analyzing Circulating Tumor Cell and ExosomeKiichi Niitsu, Taiki Nakanishi, Shunya Murakami, et al.
International Journal of Cancer|April 19, 2012
The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesotheliomaMomen Elshazley, Mitsuo Sato, Tetsunari Hase, et al.
Cancer Research|April 19, 2006
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic krasMarie Wislez, Nobukazu Fujimoto, Julie G Izzo, et al.
Cancer Science|February 7, 2017
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancerTomohiko Kakumu, Mitsuo Sato, Daiki Goto, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|February 11, 2011
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapyNoriaki Sunaga, David S Shames, Luc Girard, et al.
Experimental Cell Research|February 12, 2022
Resistance to mutant KRAS<sup>V12</sup>-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell lineNao Muraki, Mizuki Yamada, Hinako Doki, et al.
Annals of Surgical Oncology|November 17, 2011
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cellsMihoko Horio, Mitsuo Sato, Yoshihiro Takeyama, et al.
Oncology Letters|August 21, 2023
Silencing of <i>GRHL2</i> induces epithelial‑to‑mesenchymal transition in lung cancer cell lines with different effects on proliferation and clonogenic growthNozomi Kawabe, Kohei Matsuoka, Kazuki Komeda, et al.
Plos One|November 16, 2020
Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patientsNaoyuki Yogo, Tetsunari Hase, Toshihiro Kasama, et al.
Respiratory Investigation|February 11, 2026
Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitorsTatsuya Hirano, Ichidai Tanaka, Masahiro Morise, et al.
IEEE Transactions on Biomedical Circuits and Systems|November 27, 2018
A 65-nm CMOS Fully Integrated Analysis Platform Using an On-Chip Vector Network Analyzer and a Transmission-Line-Based Detection Window for Analyzing Circulating Tumor Cell and ExosomeKiichi Niitsu, Taiki Nakanishi, Shunya Murakami, et al.
International Journal of Cancer|April 19, 2012
The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesotheliomaMomen Elshazley, Mitsuo Sato, Tetsunari Hase, et al.
Cancer Research|April 19, 2006
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic krasMarie Wislez, Nobukazu Fujimoto, Julie G Izzo, et al.
Cancer Science|February 7, 2017
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancerTomohiko Kakumu, Mitsuo Sato, Daiki Goto, et al.
Pageof 13